This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McGettigan, J. P.
Right arrow Articles by Schnell, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McGettigan, J. P.
Right arrow Articles by Schnell, M. J.

 Previous Article  |  Next Article 

Journal of Virology, May 2001, p. 4430-4434, Vol. 75, No. 9
0022-538X/01/$04.00+0   DOI: 10.1128/JVI.75.9.4430-4434.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Rabies Virus-Based Vectors Expressing Human Immunodeficiency Virus Type 1 (HIV-1) Envelope Protein Induce a Strong, Cross-Reactive Cytotoxic T-Lymphocyte Response against Envelope Proteins from Different HIV-1 Isolates

James P. McGettigan,1,2 Heather D. Foley,1,2 Igor M. Belyakov,3 Jay A. Berzofsky,3 Roger J. Pomerantz,1,4,5 and Matthias J. Schnell1,4,*

The Dorrance H. Hamilton Laboratories, Center for Human Virology,1 and Departments of Biochemistry and Molecular Pharmacology,4 Microbiology and Immunology,2 and Medicine,5 Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, and Molecular Immunogenetics and Vaccine Research Section, Metabolism Branch, National Cancer Institute, Bethesda, Maryland 208923

Received 22 November 2000/Accepted 26 January 2001

Novel viral vectors that are able to induce both strong and long-lasting immune responses may be required as effective vaccines for human immunodeficiency virus type 1 (HIV-1) infection. Our previous experiments with a replication-competent vaccine strain-based rabies virus (RV) expressing HIV-1 envelope protein from a laboratory-adapted HIV-1 strain (NL4-3) and a primary HIV-1 isolate (89.6) showed that RV-based vectors are excellent for B-cell priming. Here we report that cytotoxic T-lymphocyte (CTL) responses against HIV-1 gp160 are induced by recombinant RVs. Our results indicated that a single inoculation of mice with an RV expressing HIV-1 gp160 induced a solid and long-lasting memory CTL response specific for HIV-1 envelope protein. Moreover, CTLs from immunized mice were not restricted to the homologous HIV-1 envelope protein and were able to cross-kill target cells expressing HIV-1 gp160 from heterologous HIV-1 strains. These studies further suggest promise for RV-based vectors to elicit a persistent immune response against HIV-1 and their potential utility as efficacious anti-HIV-1 vaccines.


* Corresponding author. Mailing address: 1020 Locust Street, Suite 335, Philadelphia, PA 19107-6799. Phone: (215) 503-1260. Fax: (215) 923-1956. E-mail: matthias.schnell{at}mail.tju.edu.


Journal of Virology, May 2001, p. 4430-4434, Vol. 75, No. 9
0022-538X/01/$04.00+0   DOI: 10.1128/JVI.75.9.4430-4434.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Zhao, L., Toriumi, H., Kuang, Y., Chen, H., Fu, Z. F. (2009). The Roles of Chemokines in Rabies Virus Infection: Overexpression May Not Always Be Beneficial. J. Virol. 83: 11808-11818 [Abstract] [Full Text]  
  • Pulmanausahakul, R., Li, J., Schnell, M. J., Dietzschold, B. (2008). The Glycoprotein and the Matrix Protein of Rabies Virus Affect Pathogenicity by Regulating Viral Replication and Facilitating Cell-to-Cell Spread. J. Virol. 82: 2330-2338 [Abstract] [Full Text]  
  • Bukreyev, A., Skiadopoulos, M. H., Murphy, B. R., Collins, P. L. (2006). Nonsegmented negative-strand viruses as vaccine vectors.. J. Virol. 80: 10293-10306 [Full Text]  
  • Faber, M., Lamirande, E. W., Roberts, A., Rice, A. B., Koprowski, H., Dietzschold, B., Schnell, M. J. (2005). A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies. J. Gen. Virol. 86: 1435-1440 [Abstract] [Full Text]  
  • Koser, M. L., McGettigan, J. P., Tan, G. S., Smith, M. E., Koprowski, H., Dietzschold, B., Schnell, M. J. (2004). Rabies virus nucleoprotein as a carrier for foreign antigens. Proc. Natl. Acad. Sci. USA 101: 9405-9410 [Abstract] [Full Text]  
  • McKenna, P. M., Pomerantz, R. J., Dietzschold, B., McGettigan, J. P., Schnell, M. J. (2003). Covalently Linked Human Immunodeficiency Virus Type 1 gp120/gp41 Is Stably Anchored in Rhabdovirus Particles and Exposes Critical Neutralizing Epitopes. J. Virol. 77: 12782-12794 [Abstract] [Full Text]  
  • McGettigan, J. P., Naper, K., Orenstein, J., Koser, M., McKenna, P. M., Schnell, M. J. (2003). Functional Human Immunodeficiency Virus Type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and Env Expressed from a Single Rhabdovirus-Based Vaccine Vector Genome. J. Virol. 77: 10889-10899 [Abstract] [Full Text]  
  • McGettigan, J. P., Pomerantz, R. J., Siler, C. A., McKenna, P. M., Foley, H. D., Dietzschold, B., Schnell, M. J. (2002). Second-Generation Rabies Virus-Based Vaccine Vectors Expressing Human Immunodeficiency Virus Type 1 Gag Have Greatly Reduced Pathogenicity but Are Highly Immunogenic. J. Virol. 77: 237-244 [Abstract] [Full Text]  
  • Novitsky, V., Cao, H., Rybak, N., Gilbert, P., McLane, M. F., Gaolekwe, S., Peter, T., Thior, I., Ndung'u, T., Marlink, R., Lee, T. H., Essex, M. (2002). Magnitude and Frequency of Cytotoxic T-Lymphocyte Responses: Identification of Immunodominant Regions of Human Immunodeficiency Virus Type 1 Subtype C. J. Virol. 76: 10155-10168 [Abstract] [Full Text]  
  • Foley, H. D., Otero, M., Orenstein, J. M., Pomerantz, R. J., Schnell, M. J. (2002). Rhabdovirus-Based Vectors with Human Immunodeficiency Virus Type 1 (HIV-1) Envelopes Display HIV-1-Like Tropism and Target Human Dendritic Cells. J. Virol. 76: 19-31 [Abstract] [Full Text]  
  • McGettigan, J. P., Sarma, S., Orenstein, J. M., Pomerantz, R. J., Schnell, M. J. (2001). Expression and Immunogenicity of Human Immunodeficiency Virus Type 1 Gag Expressed by a Replication-Competent Rhabdovirus-Based Vaccine Vector. J. Virol. 75: 8724-8732 [Abstract] [Full Text]